{
  "ticker": "PAR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963684",
  "id": "02963684",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250630",
  "time": "1407",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l8brclkgzhlx.pdf",
  "summary": "**Clinical Trial Update (Phase 3 Knee OA Study):**  \n- First US clinical sites activated and initial patients consented for Phase 3 PARA_OA_012 study.  \n- Trial evaluates injectable pentosan polysulfate sodium (iPPS) for moderate-to-severe knee osteoarthritis.  \n- **Key metrics:** 466 participants globally; primary endpoint is pain reduction at Day 112.  \n- **Operational progress:** 15 Australian and 50 US sites targeted; staggered activation throughout CY2025.  \n\n*No material financial or capital markets impact identified.*",
  "usage": {
    "prompt_tokens": 1223,
    "completion_tokens": 117,
    "total_tokens": 1340,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T04:45:34.488124"
}